Objective. To describe our institution’s experience with the AngioVac system. Background. Intracardiac and intravascular masses previously required surgical excision, but now, there are a number of minimally invasive options. With the advent of vacuum aspiration, more specifically the AngioVac System (AngioDynamics, NY, USA), there exists a system with both low mortality and minor complications. However, the number of retrospective studies remains limited. Outcome data for high-risk patients are also limited. Methods. Data were collected and analyzed in patients who underwent AngioVac therapy at our tertiary care center from January 2014 to December 2020. Results. Our results demonstrated a 93.3% intraoperative success rate and a 100% intraoperative survival rate. However, a number of complications, including but not limited to hematomas, anemia, and hypotension, occurred, as described below. Conclusions. Our experiences demonstrated good outcomes and continue to support the usefulness of the AngioVac System. The data also support the use of AngioVac as a treatment option for the debulking or removal of right heart masses in critically ill patients.

中文翻译：

---

利用 AngioVac 系统对右心肿块进行血管内治疗：一项为期 6 年的单中心观察研究

客观。描述我们机构使用 AngioVac 系统的经验。背景。心内和血管内肿块以前需要手术切除，但现在有许多微创选择。随着真空抽吸的出现，更具体地说是 AngioVac 系统（AngioDynamics，NY，USA），存在一种死亡率低且并发症少的系统。然而，回顾性研究的数量仍然有限。高危患者的结果数据也很有限。方法。收集并分析了 2014 年 1 月至 2020 年 12 月在我们的三级护理中心接受 AngioVac 治疗的患者的数据。结果. 我们的结果表明，术中成功率为 93.3%，术中存活率为 100%。然而，如下所述，发生了许多并发症，包括但不限于血肿、贫血和低血压。结论。我们的经验证明了良好的结果，并继续支持 AngioVac 系统的实用性。数据还支持使用 AngioVac 作为对危重患者的右心肿块进行减瘤或切除的治疗选择。